Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.
СтатьяКлинические рекомендацииСистематический обзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hicks Lisa K, Messersmith Hans J, Al Hadidi Samer, Banerjee Rahul, Derman Benjamin A, Kumar Shaji, Wildes Tanya M, Bal Susan, Bhella Sita, Chmielewski Cynthia, Costello Caitlin, Dabney Raetasha, Hartley-Brown Monique, Langerak Alan, Lipe Brea, Martin Thomas, McCurdy Arleigh, Mian Hira, Riva Eloisa, Seth Rahul, Subramanian Latha, Mikhael Joseph
Аннотация
PURPOSE: To provide updated guidance regarding the therapy for multiple myeloma.
METHODS: ASCO and Ontario Health (Cancer Care Ontario) convened a joint Expert Panel and conducted an updated systematic review of the literature.
RESULTS: The updated review identified a total of 161 relevant randomized trials.
UPDATED RECOMMENDATIONS: Daratumumab therapy may be offered to patients with high-risk smoldering myeloma. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as initial therapy for transplant eligible patients. They should also be offered at least lenalidomide maintenance, with or without daratumumab, carfilzomib, and/or dexamethasone. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as therapy for suitable transplant-ineligible patients. Patients with relapsed or refractory multiple myeloma should be offered triplet therapy or T-cell redirecting therapies according to a set of recommended principles.Additional information is available at www.asco.org/hematologic-malignancies-guidelines.
METHODS: ASCO and Ontario Health (Cancer Care Ontario) convened a joint Expert Panel and conducted an updated systematic review of the literature.
RESULTS: The updated review identified a total of 161 relevant randomized trials.
UPDATED RECOMMENDATIONS: Daratumumab therapy may be offered to patients with high-risk smoldering myeloma. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as initial therapy for transplant eligible patients. They should also be offered at least lenalidomide maintenance, with or without daratumumab, carfilzomib, and/or dexamethasone. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as therapy for suitable transplant-ineligible patients. Patients with relapsed or refractory multiple myeloma should be offered triplet therapy or T-cell redirecting therapies according to a set of recommended principles.Additional information is available at www.asco.org/hematologic-malignancies-guidelines.